{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"58.21","value":"21.6"},{"groupId":"OG001","spread":"182.6","value":"0.9"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"218"},{"groupId":"OG001","value":"111"}],"units":"Participants"}],"description":"For each on-treatment tumor marker assessment from each subject, the biochemical response of CEA was determined based on percent increase or decrease from baseline. Best biochemical response over the course of treatment was determined from evaluation of each subject's time point response data. Biochemical response: Complete Response (CR)- Decrease in tumor marker into normal range from baseline value; Partial Response (PR)- Decrease of \\>50% from baseline value when baseline value is above normal range; Stable Disease (SD)- No more than a 50% increase and no more than a 50% decrease from baseline value above normal range; Progressive Disease (PD)- Increase of \\>50% from baseline value when baseline value is above normal range / or increase from low or normal range at baseline to above normal range; Not Evaluable (NE)- Missing baseline value / or baseline value is not elevated and response is not Progressive Disease (PD) / or response can not be determined due to change in assay format.","groups":[{"description":"XL184 175 mg L-malate salt weight; 138 mg freebase equivalent weight, oral capsules once daily","id":"OG000","title":"XL184 (Cabozantinib)"},{"description":"Oral capsules once daily","id":"OG001","title":"Placebo"}],"paramType":"NUMBER","populationDescription":"For the CEA measure the analysis population differs from the Intent To Treat (ITT) population of 219 XL184 and 111 Placebo. One subject did not provide samples for CEA. The biomarker analysis was based on available samples, not on ITT.","reportingStatus":"POSTED","timeFrame":"Serum tumor markers CEA evaluated from blood samples collected at screening and every 12 weeks (± 5 days from randomization) until date of first documented progression or date of death from any cause, whichever came first, assessed for up to 34 months.","title":"Biochemical Response Carcinoembryonic Antigen (CEA) %","type":"SECONDARY","unitOfMeasure":"% of participants"}